A consortium of Chinese investors has agreed to acquire SciClone Pharmaceuticals, the US-based, China-focused specialty pharmaceutical firm, for $11.18 per share in cash. The deal, which values the pharma company at about $605 million, will be funded through a combination of equity and debt financing, a company statement said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
